Breaking news

Google Removes AI Health Overviews Following Guardian Investigation

Guardian Inquiry Spurs Change in AI Health Results

In a swift response to recent scrutiny, Google has removed its AI-generated overviews for several health-related queries following an investigation by the Guardian. The investigation uncovered that responses to queries, such as “what is the normal range for liver blood tests,” failed to account for important factors like nationality, sex, ethnicity, or age, potentially misleading users about their health status.

Selective Removal and Query Variations

According to updated findings, AI overviews have now been removed for the specific queries “what is the normal range for liver blood tests” and “what is the normal range for liver function tests.” However, related queries such as “LFT reference range” or “LFT test reference range” may still trigger AI-generated summaries. An early test conducted hours after the Guardian story confirmed that in several instances the overviews were absent, with Google even offering the option of an AI mode to handle the query. In some cases, the Guardian article documenting the change emerged as the top result.

Google’s Position and Internal Review

A Google spokesperson noted that the company does not publicly “comment on individual removals within Search” but emphasized its commitment to “making broad improvements.” An internal team of clinicians reviewed the contested queries and concluded that in many instances the information provided was accurate and supported by high-quality sources. Despite this, the selective removal highlights an ongoing challenge in balancing AI innovation with user safety in sensitive areas such as healthcare.

Industry Reactions and Broader Implications

Vanessa Hebditch, Director of Communications and Policy at the British Liver Trust, welcomed the removal as “excellent news.” However, she cautioned that focusing on a single search result misses a larger concern: the overall reliability of AI overviews in health contexts. This sentiment underscores the broader debate on the integration of AI in healthcare information delivery—a field where precision and accountability remain paramount.

Continued Evolution in Health Search Technology

Last year, Google introduced a suite of new features designed to enhance healthcare-related search outcomes, including refined overviews and dedicated health-focused AI models. While these steps signal a proactive approach, the incident highlights the persistent need for rigorous oversight as AI technologies evolve and intersect with critical health information.

China’s Humanoid Robot Boom Faces A Bigger Question: Can These Machines Make Money?

Unitree’s $9 Billion Bet On The Future Of Robotics

China’s humanoid robotics industry is attracting huge investor interest, but as Unitree Robotics prepares for its public debut, questions are growing over whether its robots can move beyond impressive acrobatics and become commercially viable tools.

The Hangzhou-based startup priced its IPO at 150.8 yuan ($22.4) per share, raising $900 million and valuing the company at 61 billion yuan, or about $9 billion. The offering attracted record retail demand on Shanghai’s STAR Market, with the online tranche oversubscribed more than 5,000 times and a winning rate of just 0.018%. Strategic investors included AI startup DeepSeek.

A Unitree-linked pre-IPO perpetual contract was trading at roughly four times the IPO price on Friday, highlighting the speculative interest surrounding the company.

Unitree is known for robots capable of kung fu kicks, backflips and recovering from falls. Yet analysts question whether the technology is ready for large-scale commercial use. “For these humanoid robots, to be honest, they’re fascinating. They can dance and all that, but I’ve never seen them doing any real housework,” said Hao Hong, managing partner of Lotus Asset Management.

In its prospectus, Unitree warned that mass adoption could take longer than expected because robotic hands are still not precise or durable enough for sustained use.

From Acrobatic Robots To Commercial Machines

Even advanced humanoid robots can currently perform only a limited number of tasks and typically operate for a few hours before recharging, according to Dominik Pross, an equity analyst at VP Bank. Most models run for up to four hours, while robots also need to be trained for individual tasks.

“Robots have to be specifically trained for each and every task entrusted to them, even the simplest,” Pross said.

More robotics listings are expected, with Unitree rivals AgiBot and Leju Robotics seeking listings in Hong Kong and Shenzhen. LimX Dynamics founder Will Zhang said last month that “listing is a must.”

China’s Cost Advantage

China’s manufacturing scale has helped it establish a leading position in robotics. Wood Mackenzie expects the global humanoid robot fleet to surpass 10 million units by 2035, while China already accounts for more than 70% of global industrial robot installations and nearly 90% of humanoids deployed last year.

Average humanoid robot prices fell 93% between 2020 and 2025 to $58,000. Unitree’s flagship G1 costs $16,000, while SemiAnalysis estimates that the company has cut the price of its G1 EDU model by more than 45% to $27,300, while maintaining a 67% gross margin.

Falling prices and government support are attracting investment, but analysts say it will take time to prove that humanoid robots can generate strong returns. Unitree’s revenue more than quadrupled last year, although adjusted first-quarter profit fell more than 52% as research and development and marketing spending increased. Nearly three-quarters of its humanoid revenue in the first nine months of 2025 came from research and education, highlighting the gap between demonstrations and widespread commercial use.

“Unlike many early-stage robotics companies, the Unitree story is backed by real revenue growth,” said Jeff Ko, chief analyst at CoinEx. Still, he noted that its $9 billion valuation, at more than 200 times last year’s earnings, reflects significant speculative interest.

Geopolitical Risks

Unitree’s IPO momentum has continued despite growing pressure on Chinese robotics companies. The U.S. moved last month to ban imports of foreign-made humanoid and four-legged robots, potentially exposing Unitree, which generated about 13% of its revenue from the U.S. last year.

Access to Nvidia hardware and software is another risk, as Chinese robotics companies rely on the technology to power their systems. “Chinese robot producers are not yet in a position to do without Western components completely,” Pross said.

China’s control over rare earths used in robot actuators and motors could nevertheless give its manufacturers an advantage, according to Bernstein analyst Dien Wang.

The Bigger Robotics Opportunity

The potential market is attracting major players, including Tesla, whose CEO Elon Musk is expanding production plans for Optimus humanoid robots. At the same time, some researchers argue that the future of robotics will not be limited to humanoids: quadruped and purpose-built robots can be cheaper and more reliable for repetitive industrial tasks, while humanoids may be better suited to unpredictable environments.

For Unitree, the challenge is no longer proving that its robots can perform impressive tricks. It is proving that they can do enough useful work to justify a $9 billion valuation.

Uol
Aretilaw firm
The Future Forbes Realty Global Properties
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter